EichorEICHOR
Condition: Metastatic Non Cutaneous Melanoma Synced from ClinicalTrials.gov · August 07, 2026

Recruiting studies: Metastatic Non Cutaneous Melanoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Study to Evaluate Impact® as Support to Anti PD1 or Anti PD1 Based Regimen Treatment in Patients With Inoperable Locally
NA · 1 location(s) · Fondazione Melanoma Onlus · NCT06880198Adjuvant Tebentafusp in High Risk Ocular Melanoma
Phase 3 · 15 location(s) · European Organisation for Research and Treatment of Cancer - · NCT06246149A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectabl
Phase 2 · 31 location(s) · Innovent Biologics (Suzhou) Co. Ltd. · NCT06797297A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
Phase 1/Phase 2 · 4 location(s) · OncoResponse, Inc. · NCT06090266A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Phase 1 · 12 location(s) · Pliant Therapeutics, Inc. · NCT06270706A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Phase 1/Phase 2 · 5 location(s) · 7 Hills Pharma, LLC · NCT06362369Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Phase 1/Phase 2 · 21 location(s) · Revolution Medicines, Inc. · NCT05379985MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
Phase 1 · 2 location(s) · Memgen, Inc. · NCT05076760SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Phase N/A · 68 location(s) · Massive Bio, Inc. · NCT03452774Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The K
Phase 4 · 1 location(s) · OHSU Knight Cancer Institute · NCT07405086A Study of MGC026 in Participants With Advanced Solid Tumors
Phase 1 · 12 location(s) · MacroGenics · NCT06242470A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works
Phase 1/Phase 2 · 11 location(s) · Regeneron Pharmaceuticals · NCT06413680Electrochemotherapy (ECT) in Patients With Primary Visceral Tumors and/or Secondary Visceral Localizations, of Any Histo
NA · 1 location(s) · Istituto Oncologico Veneto IRCCS · NCT06753136Safety and Efficacy of OBX-115 in Advanced Solid Tumors
Phase 1/Phase 2 · 10 location(s) · Obsidian Therapeutics, Inc. · NCT06060613Binimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma Treatment
Phase N/A · 59 location(s) · Pierre Fabre Pharma GmbH · NCT04045691SL-28 for Advanced Solid Tumours
Phase 1/Phase 2 · 1 location(s) · Second Life Therapeutics · NCT07341737WoW - Single- vs Two-staged Excisions of Thin Melanoma
NA · 1 location(s) · Vastra Gotaland Region · NCT06363591A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants W
Phase 1/Phase 2 · 32 location(s) · Marengo Therapeutics, Inc. · NCT05592626Efficacy And Safety Of Anti-PD-1/PD-L1 Antibodies In Combination With Bevacizumab And Metronomic Cyclophosphamide In Pat
Phase 2 · 1 location(s) · EuroCityClinic LLC · NCT07130032A Beta-only IL-2 ImmunoTherapY Study
Phase 1/Phase 2 · 27 location(s) · Medicenna Therapeutics, Inc. · NCT05086692Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers
Phase 1/Phase 2 · 1 location(s) · Hadassah Medical Organization · NCT05296564Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Mayo Clinic · NCT05269381Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Meta
Phase 1/Phase 2 · 42 location(s) · Inhibrx Biosciences, Inc · NCT04198766Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Essen Biotech · NCT07410494Genomic Investigation of Unusual Responders
Phase N/A · 1 location(s) · University Health Network, Toronto · NCT03740503Stereotactic Ablative Radiotherapy (XRT) and Immunotherapy for Oligometastatic Extracranial Melanoma
Phase 2 · 5 location(s) · Melanoma Institute Australia · NCT06767306A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Phase 2 · 85 location(s) · Daiichi Sankyo · NCT06172478A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3
Phase N/A · 2 location(s) · Replimune, Inc. · NCT06887348A Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic S
Phase 1 · 1 location(s) · Hefei TG ImmunoPharma Co., Ltd. · NCT07376707Dabrafenib and/or Trametinib Rollover Study
Phase 4 · 32 location(s) · Novartis Pharmaceuticals · NCT03340506
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.